Interferon (1 RCT; 66 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes interferon (1 RCT; 66 participants) compared with placebo (very low certainty).
4 findings from 1 review
HR 0.41 [0.18, 0.94]
1 study · 66 participants
Very low
OR 4.03 [0.86, 18.8]
2 studies · 86 participants
Very low
HR 0.27 [0.07, 1.1]
1 study · 66 participants
Very low
Show 1 more finding
Sunitinib (1 RCT; 171 participants)
Estimates of effects, ranking, and certainty of evidence for… probably leads to lower sunitinib (1 RCT; 171 participants) compared with placebo (moderate certainty).
2 findings from 1 review
Everolimus + bevacizumab + SSA (1 RCT; 150 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes everolimus + bevacizumab + SSA (1 RCT; 150 participants) compared with placebo (very low certainty).
1 finding from 1 review
Surufatinib (1 RCT; 172 participants)
Estimates of effects, ranking, and certainty of evidence for… leads to lower surufatinib (1 RCT; 172 participants) compared with placebo (high certainty).
2 findings from 1 review
SSA (3 RCTs; 586 participants)
Estimates of effects, ranking, and certainty of evidence for… probably leads to lower SSA (3 RCTs; 586 participants) compared with placebo (moderate certainty).
4 findings from 1 review
HR 0.51 [0.34, 0.77]
3 studies · 586 participants
Moderate
OR 2.93 [1.36, 6.32]
7 studies · 796 participants
Moderate
HR 0.34 [0.16, 0.76]
5 studies · 492 participants
High
Show 1 more finding
Placebo (4 RCT; 789 participants)
4 findings from 1 review
no estimate extracted
4 studies · 844 participants
GRADE not reported
no estimate extracted
4 studies · 789 participants
GRADE not reported
no estimate extracted
4 studies · 531 participants
GRADE not reported
Show 1 more finding
Total studies: 11 Total participants: 1338
1 finding from 1 review
no estimate extracted
11 participants
GRADE not reported
177‐Lu‐DOTATATE + SSA (1 RCT; 229 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes 177‐Lu‐DOTATATE + SSA (1 RCT; 229 participants) compared with placebo (very low certainty).
2 findings from 1 review
Surufatinib (1 RCT; 198 participants)
Estimates of effects, ranking, and certainty of evidence for… probably leads to higher surufatinib (1 RCT; 198 participants) compared with placebo (moderate certainty).
2 findings from 1 review
Streptozocin + 5‐FU (1 RCT; 20 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes streptozocin + 5‐FU (1 RCT; 20 participants) compared with placebo (very low certainty).
1 finding from 1 review
OR 0.13 [0, 4.58]
1 study · 5 participants
Very low
Total studies: 9 Total participants: 1311Â
1 finding from 1 review
no estimate extracted
9 participants
GRADE not reported
Intervention not reported
Supportive care only*** (1 RCT, 81 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40); radiotherapy with 60 Gy in…
1 finding from 1 review
Intervention not reported
TMZ (3 RCTs, 538 participants) · elderly people with newly diagnosed glioblastoma Interventions: chemoradiotherapy (CRT); chemoradiotherapy plus bevacizumab (BEV_CRT);…
The intervention showed no clear difference in TMZ (3 RCTs, 538 participants) (low certainty).
1 finding from 1 review
Intervention not reported
CRT (2 RCTs; 635 participants) · elderly people with newly diagnosed glioblastoma Interventions: chemoradiotherapy (CRT); chemoradiotherapy plus bevacizumab (BEV_CRT);…
The intervention leads to lower CRT (2 RCTs; 635 participants) (high certainty).
1 finding from 1 review
Intervention not reported
BEV_CRT (1 RCT; 73 participants) · elderly people with newly diagnosed glioblastoma Interventions: chemoradiotherapy (CRT); chemoradiotherapy plus bevacizumab (BEV_CRT);…
The intervention probably leads to lower BEV_CRT (1 RCT; 73 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
RT 60 (5 RCTs; 713 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT 40); chemoradiotherapy (CRT);…
1 finding from 1 review
Intervention not reported
RT 40 (4 RCTs; 930 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT 40); chemoradiotherapy (CRT);…
The intervention showed no clear difference in RT 40 (4 RCTs; 930 participants) (low certainty).
1 finding from 1 review
Intervention not reported
BEV_RT (1 RCT; 75 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT 40); chemoradiotherapy (CRT);…
It is very uncertain whether the intervention changes BEV_RT (1 RCT; 75 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
TMZ (3 RCTs, 538 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT 40); chemoradiotherapy (CRT);…
It is very uncertain whether the intervention changes TMZ (3 RCTs, 538 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
CRT (2 RCTs; 635 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT 40); chemoradiotherapy (CRT);…
The intervention may leads to lower CRT (2 RCTs; 635 participants) (low certainty).
1 finding from 1 review